AR and neoplasm: We are therefore working to add AMACR and p63 to our flow cytometry panel and are also planning to include global genomic and transcriptomic analyses of our PDCOs to evaluate for tumor-specific molecular alterations such as ERG, AR splice-variants, and NEPC markers.